Chronic Myelomonocytic Leukemia Gold Jubilee
Open Access
- 1 July 2021
- Vol. 2 (3), 403-428
- https://doi.org/10.3390/hemato2030026
Abstract
Chronic myelomonocytic leukemia (CMML) was named 50 years ago to describe a myeloid malignancy whose onset is typically insidious. This disease is now classified by the World Health Organisation as a myelodysplastic syndrome (MDS)-myeloproliferative neoplasm (MPN) overlap disease. Observed mostly in ageing people, CMML is characterized by the expansion of monocytes and, in many cases, granulocytes. Abnormal repartition of circulating monocyte subsets, as identified by flow cytometry, facilitates disease recognition. CMML is driven by the accumulation, in the stem cell compartment, of somatic variants in epigenetic, splicing and signaling genes, leading to epigenetic reprogramming. Mature cells of the leukemic clone contribute to creating an inflammatory climate through the release of cytokines and chemokines. The suspected role of the bone marrow niche in driving CMML emergence and progression remains to be deciphered. The clinical expression of the disease is highly diverse. Time-dependent accumulation of symptoms eventually leads to patient death as a consequence of physical exhaustion, multiple cytopenias and acute leukemia transformation. Fifty years after its identification, CMML remains one of the most severe chronic myeloid malignancies, without disease-modifying therapy. The proliferative component of the disease that distinguishes CMML from severe MDS has been mostly neglected. This review summarizes the progresses made in disease understanding since its recognition and argues for more CMML-dedicated clinical trials.Keywords
This publication has 218 references indexed in Scilit:
- TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASSThe EMBO Journal, 2013
- IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia DevelopmentCancer Cell, 2011
- Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemiaJCI Insight, 2011
- Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2Nature, 2010
- Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesBlood, 2009
- Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasmsBlood, 2009
- Mutation inTET2in Myeloid CancersThe New England Journal of Medicine, 2009
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AMLBlood, 2009
- Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic CorrelatesCancer Cell, 2008
- Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK functionProceedings of the National Academy of Sciences of the United States of America, 2008